Two case reports of delayed-allergic reactions to clindamycin confirmed with a positive lymphocyte transformation test
Summary: Clindamycin is widely used in the prophylaxis and treatment of infections due to its broad spectrum of antimicrobial activity. Hypersensitivity to clindamycin seems to be not very common (less than 1% of drug-allergic reactions) and it mostly appears as delayed T-cell mediated. For the diagnosis, skin testing is considered to be highly sensitive and rather safe, but cutaneous and systemic reactions have been described. Provocation test is considered the gold standard. However, it includes the possibility of severe reactions. We reported two cases of delayed allergic reaction to clindamycin, confirmed with a positive lymphocyte transformation test, showing this in vitro test like a promising diagnostic method because of its usefulness and safety.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
European annals of allergy and clinical immunology - 52(2020), 2 vom: 07. März, Seite 91-93 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vílchez-Sánchez, F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3U02EL437C |
|---|
| Anmerkungen: |
Date Completed 30.06.2021 Date Revised 30.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.23822/EurAnnACI.1764-1489.117 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30272544X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30272544X | ||
| 003 | DE-627 | ||
| 005 | 20231225111329.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.23822/EurAnnACI.1764-1489.117 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1009.xml |
| 035 | |a (DE-627)NLM30272544X | ||
| 035 | |a (NLM)31668055 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vílchez-Sánchez, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Two case reports of delayed-allergic reactions to clindamycin confirmed with a positive lymphocyte transformation test |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.06.2021 | ||
| 500 | |a Date Revised 30.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Summary: Clindamycin is widely used in the prophylaxis and treatment of infections due to its broad spectrum of antimicrobial activity. Hypersensitivity to clindamycin seems to be not very common (less than 1% of drug-allergic reactions) and it mostly appears as delayed T-cell mediated. For the diagnosis, skin testing is considered to be highly sensitive and rather safe, but cutaneous and systemic reactions have been described. Provocation test is considered the gold standard. However, it includes the possibility of severe reactions. We reported two cases of delayed allergic reaction to clindamycin, confirmed with a positive lymphocyte transformation test, showing this in vitro test like a promising diagnostic method because of its usefulness and safety | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a allergy | |
| 650 | 4 | |a clindamycin | |
| 650 | 4 | |a delayed reaction | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a lymphocyte transformation test | |
| 650 | 7 | |a Allergens |2 NLM | |
| 650 | 7 | |a Clindamycin |2 NLM | |
| 650 | 7 | |a 3U02EL437C |2 NLM | |
| 700 | 1 | |a Domínguez-Ortega, J |e verfasserin |4 aut | |
| 700 | 1 | |a González Muñoz, M |e verfasserin |4 aut | |
| 700 | 1 | |a Loli-Ausejo, D |e verfasserin |4 aut | |
| 700 | 1 | |a Heredia-Revuelto, R |e verfasserin |4 aut | |
| 700 | 1 | |a Fiandor Román, A |e verfasserin |4 aut | |
| 700 | 1 | |a Quirce, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European annals of allergy and clinical immunology |d 2003 |g 52(2020), 2 vom: 07. März, Seite 91-93 |w (DE-627)NLM124169147 |x 1764-1489 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2020 |g number:2 |g day:07 |g month:03 |g pages:91-93 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.23822/EurAnnACI.1764-1489.117 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2020 |e 2 |b 07 |c 03 |h 91-93 | ||